Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
肿瘤
/
血管生成
蛋白质酪氨酸激酶 肿瘤干细胞
/
FGFR
VEGFR
/ PD173074

PD173074 {[allProObj[0].p_purity_real_show]}

货号：A150425

PD173074是一种有效的FGFR1抑制剂，IC50为25 nM。它还抑制VEGFR2的活性，IC50为100-200 nM，对FGFR1与PDGFR和c-Src的选择性超过1000倍。

PD173074 化学结构 CAS号：219580-11-7
PD173074 化学结构
CAS号：219580-11-7
PD173074 3D分子结构
CAS号：219580-11-7
PD173074 化学结构 CAS号：219580-11-7
PD173074 3D分子结构 CAS号：219580-11-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

PD173074 纯度/质量文件 产品仅供科研

货号：A150425 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 FGFR ↓ FGFR1 ↓ FGFR2 ↓ FGFR3 ↓ FGFR4 ↓ 其他靶点 纯度
Tyrphostin AG1296 +

FGFR (Swiss 3T3), IC50: 12.3 μM

 		PDGFR 99%+
Pazopanib +

FGFR, IC50: 140 nM

 		99%
Erdafitinib ✔ RET 99%+
Gambogenic acid ✔ 98+%
Sulfatinib +++

FGFR1, IC50: 15 nM

 		99+%
Nintedanib esylate +

FGFR1, IC50: 69 nM

 		++

FGFR2, IC50: 37 nM

 		+

FGFR3, IC50: 108 nM

 		98%
Zoligratinib +++

FGFR1, IC50: 9.3 nM

 		+++

FGFR2, IC50: 7.6 nM

 		++

FGFR3, IC50: 22 nM

 		+

FGFR4, IC50: 290 nM

 		99%+
MK-2461 +

FGFR1, IC50: 65 nM

 		++

FGFR2, IC50: 39 nM

 		++

FGFR3, IC50: 50 nM

 		98%+
SU 5402 ++

FGFR1, IC50: 30 nM

 		98%
Brivanib +

FGFR1, IC50: 148 nM

 		99%+
Lucitanib ++

FGFR1, IC50: 17.5 nM

 		+

FGFR2, IC50: 82.5 nM

 		99%+
Ponatinib ++++

FGFR1, IC50: 2.2 nM

 		98%
PD-166866 +

FGFR1, IC50: 52.4 nM

 		98%
Narazaciclib ++

FGFR1, IC50: 26 nM

 		RET 99%+
Lactate +++

FGFR1, IC50: 8 nM

 		+++

FGFR3, IC50: 9 nM

 		c-Kit,FLT3 85%
Lenvatinib mesylate ++

FGFR1, IC50: 46 nM

 		c-RET 99%
LY2874455 ++++

FGFR1, IC50: 2.8 nM

 		++++

FGFR2, IC50: 2.6 nM

 		+++

FGFR3, IC50: 6.4 nM

 		+++

FGFR4, IC50: 6 nM

 		99%+
FIIN-2 +++

FGFR1, IC50: 3.09 nM

 		+++

FGFR2, IC50: 4.3 nM

 		++

FGFR3, IC50: 27 nM

 		++

FGFR4, IC50: 45.3 nM

 		98%
FIIN-3 +++

FGFR1, IC50: 13.1 nM

 		++

FGFR2, IC50: 21 nM

 		++

FGFR3, IC50: 31.4 nM

 		++

FGFR4, IC50: 35.3 nM

 		98%
Infigratinib ++++

FGFR1, IC50: 0.9 nM

 		++++

FGFR2, IC50: 1.4 nM

 		++++

FGFR3, IC50: 1.0 nM

FGFR3 (K650E), IC50: 4.9 nM

 		+

FGFR4, IC50: 60 nM

 		99%+
Danusertib ++

FGFR1, IC50: 47 nM

 		RET 99%+
R1530 ++

FGFR1, IC50: 28 nM

 		98%
ENMD-2076 +

FGFR1, IC50: 92.7 nM

 		+

FGFR2, IC50: 70.8 nM

 		RET,FLT3 98%
Dovitinib +++

FGFR1, IC50: 8 nM

 		+++

FGFR3, IC50: 9 nM

 		c-Kit,FLT3 99%+
Sorafenib +

FGFR1, IC50: 580 nM

 		99%
SSR128129E +

FGFR1, IC50: 1.9 μM

 		99%+
AZD-4547 ++++

FGFR1, IC50: 0.2 nM

 		++++

FGFR2, IC50: 2.5 nM

 		++++

FGFR3, IC50: 1.8 nM

 		98%
Lenvatinib ++

FGFR1, IC50: 46 nM

 		RET 98%
PD173074 ++

FGFR1, IC50: ~25 nM

 		99%+
S49076 ++

FGFR1, IC50: 18 nM

 		+++

FGFR2, IC50: 17 nM

 		+++

FGFR3, IC50: 15 nM

 		98%
Futibatinib ++++

FGFR1, IC50: 1.8 nM

 		++++

FGFR2, IC50: 1.4 nM

 		++++

FGFR3, IC50: 1.6 nM

 		+++

FGFR4, IC50: 3.7 nM

 		99%+
Ferulic Acid +

FGFR1, IC50: 3.78 μM

 		+

FGFR2, IC50: 12.5 μM

 		98%
Nintedanib +

FGFR1, IC50: 69 nM

 		++

FGFR2, IC50: 37 nM

 		+

FGFR3, IC50: 108 nM

 		+

FGFR4, IC50: 610 nM

 		99+%
ASP5878 ++++

FGFR1, IC50: 0.47 nM

 		++++

FGFR2, IC50: 0.6 nM

 		++++

FGFR3, IC50: 0.74 nM

 		+++

FGFR4, IC50: 3.5 nM

 		98%
PRN1371 ++++

FGFR1, IC50: 0.6 nM

 		++++

FGFR2, IC50: 1.3 nM

 		+++

FGFR3, IC50: 4.1 nM

 		++

FGFR4, IC50: 19.3 nM

 		99%
Derazantinib +++

FGFR1, IC50: 4.5 nM

 		++++

FGFR2, IC50: 1.8 nM

 		+++

FGFR3, IC50: 4.5 nM

 		++

FGFR4, IC50: 34 nM

 		RET 99%+
ODM-203 +++

FGFR1, IC50: 11 nM

 		+++

FGFR2, IC50: 16 nM

 		+++

FGFR3, IC50: 6 nM

 		++

FGFR4, IC50: 35 nM

 		99%+
Pemigatinib ++++

FGFR1, IC50: 0.4 nM

 		++++

FGFR2, IC50: 0.5 nM

 		++++

FGFR3, IC50: 1.2 nM

 		++

FGFR4, IC50: 30 nM

 		99%+
SKLB 610 ✔ PDGFR 99%+
Alofanib ✔ 99%+
Lirafugratinib ✔ 98%
Masitinib mesylate ✔ FAK 99%+
BLU9931 +

FGFR3, IC50: 150 nM

 		+++

FGFR4, IC50: 3 nM

 		99%+
BO-264 ✔ 99%+
Fisogatinib +++

FGFR4, IC50: 5 nM

 		99%+
H3B-6527 ++++

FGFR4, IC50: <1.2 nM

 		99%+
Roblitinib ++++

FGFR4, IC50: 1.9 nM

 		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。
产品名称 VEGFR1 ↓ VEGFR2 ↓ VEGFR3 ↓ 其他靶点 纯度
Motesanib Diphosphate ++++

VEGFR1, IC50: 2 nM

 		++++

VEGFR2/Flk1, IC50: 3 nM

VEGFR2, IC50: 3 nM

 		+++

VEGFR3, IC50: 6 nM

 		RET,PDGFR 98%
Tivozanib ++

VEGFR1, IC50: 30 nM

 		+++

VEGFR2, IC50: 6.5 nM

 		++

VEGFR3, IC50: 15 nM

 		99%+
Brivanib +

VEGFR1, IC50: 380 nM

 		++

Flk1, IC50: 25 nM

VEGFR2, IC50: 25 nM

 		99%+
Regorafenib +++

VEGFR1, IC50: 13 nM

 		+++

VEGFR2, IC50: 4.2 nM

 		+

VEGFR3, IC50: 46 nM

 		RET 98%
Pazopanib +++

VEGFR1, IC50: 10 nM

 		++

VEGFR2, IC50: 30 nM

 		+

VEGFR3, IC50: 47 nM

 		FGFR,c-Kit,PDGFR 99%
Sitravatinib +++

VEGFR1 (FLT1), IC50: 6 nM

 		+++

VEGFR2 (KDR), IC50: 5 nM

 		++++

VEGFR3 (FLT4), IC50: 2 nM

 		99%+
Foretinib +++

VEGFR1/FLT1, IC50: 6.8 nM

 		++++

KDR, IC50: 0.86 nM

 		++++

VEGFR3/FLT4, IC50: 2.8 nM

 		Tie-2 99%+
MGCD-265 analog ++++

VEGFR1, IC50: 3 nM

 		++++

VEGFR2, IC50: 3 nM

 		++++

VEGFR3, IC50: 4 nM

 		Tie-2 99%+
Lactate +++

VEGFR1/FLT1, IC50: 10 nM

 		+++

VEGFR2/Flk1, IC50: 13 nM

 		+++

VEGFR3/FLT4, IC50: 8 nM

 		c-Kit,FLT3 85%
AEE788 +

FLT1, IC50: 59 nM

 		+

KDR, IC50: 77 nM

 		EGFR 98+%
Linifanib ++++

VEGFR1/FLT1, IC50: 3 nM

 		++++

VEGFR2/KDR, IC50: 4 nM

 		+

VEGFR3/FLT4, IC50: 190 nM

 		FLT3 99%+
Vatalanib 2HCl +

VEGFR1/FLT1, IC50: 77 nM

 		++

VEGFR2/KDR, IC50: 37 nM

VEGFR2/Flk1, IC50: 270 nM

 		+

VEGFR3/FLT4, IC50: 660 nM

 		c-Kit,c-Fms 99%+
Axitinib ++++

VEGFR1/FLT1, IC50: 0.1 nM

 		++++

VEGFR2/KDR, IC50: 0.2 nM

VEGFR2/Flk1, IC50: 0.18 nM

 		98%
Dovitinib +++

VEGFR1/FLT1, IC50: 10 nM

 		+++

VEGFR2/Flk1, IC50: 13 nM

 		+++

VEGFR3/FLT4, IC50: 8 nM

 		c-Kit,FLT3 99%+
ZM 306416 +

VEGFR1, IC50: 0.33 μM

 		Src 99%+
KRN-633 +

VEGFR1, IC50: 170 nM

 		+

VEGFR2, IC50: 160 nM

 		+

VEGFR3, IC50: 125 nM

 		c-Kit,BTK 98%
OSI-930 +++

FLT1, IC50: 8 nM

 		+++

KDR, IC50: 9 nM

 		99%+
Lenvatinib ++

VEGFR1/FLT1, IC50: 22 nM

 		++++

VEGFR2/KDR, IC50: 4.0 nM

 		+++

VEGFR3/FLT4, IC50: 5.2 nM

 		98%
NVP-BAW2881 +

hVEGFR1, IC50: 820 nM

 		+++

mVEGF2, IC50: 165 nM

hVEGFR2, IC50: 9 nM

 		+

hVEGFR3, IC50: 420 nM

 		98%
Cediranib +++

VEGFR1/FLT1, IC50: 5 nM

 		++++

VEGFR2/KDR, IC50: 0.5 nM

 		c-Kit 99%+
Nintedanib ++

VEGFR1, IC50: 34 nM

 		+++

VEGFR2, IC50: 13 nM

 		+++

VEGFR3, IC50: 13 nM

 		FLT3 99+%
BMS-794833 ++

VEGFR2, IC50: 15 nM

 		99%+
SKLB1002 ++

VEGFR2, IC50: 32 nM

 		98%
Cabozantinib S-malate ++++

VEGFR2/KDR, IC50: 0.035 nM

 		99+%
Ki8751 ++++

VEGFR2, IC50: 0.9 nM

 		c-Kit 98+%
SU 5402 ++

VEGFR2, IC50: 20 nM

 		98%
Rivoceranib Mesylate ++++

VEGFR2, IC50: 1 nM

 		RET 98+%
Ponatinib ++++

VEGFR2, IC50: 1.5 nM

 		98%
LY2874455 +++

VEGFR2, IC50: 7 nM

 		99%+
ZM323881 HCl ++++

VEGFR2, IC50: <2 nM

 		98%
AZD2932 +++

VEGFR-2, IC50: 8 nM

 		c-Kit 98%
Cabozantinib ++++

VEGFR2/KDR, IC50: 0.035 nM

 		98%
Sorafenib ++

VEGFR2/Flk1, IC50: 90 nM

VEGFR2, IC50: 90 nM

 		99%
CYC-116 ++

VEGFR2, Ki: 44 nM

 		FLT3 99%+
Golvatinib ++

VEGFR2, IC50: 16 nM

 		99%+
Sunitinib +

VEGFR2 , IC50: 80 nM

 		FLT3 98%
RAF265 ++

VEGFR2, EC50: 30 nM

 		99%+
PD173074 99%+
BFH772 ++++

VEGFR2, IC50: 3 nM

 		98%
Semaxinib +

VEGFR2/Flk1, IC50: 1.23 μM

 		98%
Vandetanib ++

VEGFR2, IC50: 40 nM

 		+

VEGFR3, IC50: 110 nM

 		EGFR 98%
SAR131675 ++

VEGFR3, IC50: 23 nM

 		99%+
ENMD-2076 +

VEGFR2/KDR, IC50: 58.2 nM

 		++

VEGFR3/FLT4, IC50: 15.9 nM

 		RET,FLT3 98%
Telatinib +++

VEGFR2, IC50: 6 nM

 		++++

VEGFR3, IC50: 4 nM

 		c-Kit 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

PD173074 生物活性

靶点

  • VEGFR2

    VEGFR2, IC50:100 nM-200 nM

  • FGFR1

    FGFR1, IC50:~25 nM
描述 Angiogenesis, playing a major role in the progression of human diseases such as diabetic retinopathy, atherosclerosis and cancer, involves the concerted action of a number of polypeptide factors such as VEGF, Ang1 and FGF. PD173074 is a selective dual inhibitor of both FGFR1 and VEGFR2 with IC50 value of 21.5nM (measured by kinase activity) and 100-200nM (measured by VEGFR2 auto-phosphorylation in NIH 3T3 cells), respectively. PD173074 inhibited auto-phosphorylation of FGFR1, induced by aFGF and heparin, of NIH-3T3 cells expressing FGFR1 endogenously in a dose-dependent manner with an IC50 in the range 1–5nM, as well as auto-phosphorylation of overexpressed VEGFR2 stimulated with VEGF (100ng/ml) with an IC50 of 100–200nM. Mice treated daily with PD173074 by intraperitoneal injection per day starting 3 days prior to pellet implantation exhibited inhibition of bFGF-induced neovascularization by 86% at a dose of 1mg/kg, as well as inhibition of VEGF induced neovascularization by 81% at a dose of 2mg/kg[1]. PD173704 can specifically and effectively inhibit multiple FGF-2-mediated responses of both oligodendrocyte progenitors, as well as differentiated oligodendrocytes with complete antagonization on two phenotypic alterations, downregulation of myelin proteins, and their re-entry into the cell cycle[2].
作用机制 PD173074 is an ATP-competitive inhibitor of FGFR1.[1]

PD173074 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
A204 Growth Inhibition Assay IC50=3.92075 μM SANGER
A2058 Growth Inhibition Assay IC50=35.6061 μM SANGER
A253 Growth Inhibition Assay IC50=15.3869 μM SANGER
A2780 Growth Inhibition Assay IC50=11.0308 μM SANGER

PD173074 动物研究

Dose Nude Mice[3]: 12 mg/kg Mice: 1 mg/kg, 2 mg/kg[1] (i.p.), 25 mg/kg - 100 mg/kg[4] (p.o.)
Administration i.p., p.o.

PD173074 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.55mL

1.91mL

0.95mL

19.10mL

3.82mL

1.91mL

PD173074 技术信息

CAS号219580-11-7
分子式C28H41N7O3
分子量 523.67
别名
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C
溶解度

DMSO: 105 mg/mL(200.51 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 2 mg/mL clear

PO 0.5% CMC-Na 35 mg/mL suspension

Tags: PD173074 | 219580-11-7 | PD 173074 | PD-173074 | FGFR1 Inhibitor | Protein Tyrosine Kinase/RTK | Apoptosis | FGFR | VEGFR | Apoptosis | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | PD173074 纯度/质量文件 | PD173074 亚型比较 | PD173074 生物活性 | PD173074 细胞研究 | PD173074 动物研究 | PD173074 实验方案 | PD173074 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z